Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines

JAMA

17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who express vaccine hesitancy. 

Vaccine hesitancy often is predicated on the concern of an individual or family members regarding the risk of an adverse event following immunisation. But for each licensed vaccine, the relative risk of an untoward event, such as contracting the disease, is greater among those who remain unvaccinated. 

Before US FDA licensure, vaccine safety must be determined by demonstration that the benefit from disease prevention exceeds the risk of adverse reactions associated with the vaccine.

Read JAMA Viewpoint article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Regulation , Vaccine , Value